Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Lynette Marie Sholl, M.D.

Co-Author

This page shows the publications co-authored by Lynette Sholl and Cloud Paweletz.
Connection Strength

1.819
  1. Traditional Diagnostics versus Disruptive Technology: The Role of the Pathologist in the Era of Liquid Biopsy. Cancer Res. 2020 08 15; 80(16):3197-3199.
    View in: PubMed
    Score: 0.905
  2. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA. Lung Cancer. 2019 08; 134:96-99.
    View in: PubMed
    Score: 0.210
  3. Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer. JAMA Oncol. 2017 06 01; 3(6):740-741.
    View in: PubMed
    Score: 0.183
  4. Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer. Sci Transl Med. 2021 09; 13(609):eabb3738.
    View in: PubMed
    Score: 0.061
  5. Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. Cancer Discov. 2021 Aug; 11(8):1952-1969.
    View in: PubMed
    Score: 0.059
  6. Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clin Cancer Res. 2021 03 15; 27(6):1604-1611.
    View in: PubMed
    Score: 0.059
  7. Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. Clin Cancer Res. 2020 06 01; 26(11):2615-2625.
    View in: PubMed
    Score: 0.055
  8. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol. 2018 11 01; 4(11):1527-1534.
    View in: PubMed
    Score: 0.050
  9. Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer. Cancer Discov. 2019 01; 9(1):34-45.
    View in: PubMed
    Score: 0.050
  10. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 12 01; 24(23):5963-5976.
    View in: PubMed
    Score: 0.050
  11. Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping. Lung Cancer. 2018 08; 122:72-75.
    View in: PubMed
    Score: 0.049
  12. Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discov. 2016 12; 6(12):1334-1341.
    View in: PubMed
    Score: 0.044
  13. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. JCI Insight. 2016 09 08; 1(14):e89014.
    View in: PubMed
    Score: 0.043
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.